ResMed (RMD) Reports In-Line Q3 EPS, Miss on Revenues
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $228.35 --0%
EPS Growth %: +5.5%
Financial Fact:
Cost of sales: 196.27M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +5.5%
Financial Fact:
Cost of sales: 196.27M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q3 EPS of $0.71, in-line with the analyst estimate of $0.71. Revenue for the quarter came in at $514.2 million versus the consensus estimate of $519.87 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
- Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
- Freedom Broker Upgrades Costco Wholesale (COST) to Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
